Amundi Has $14.03 Million Stock Holdings in Henry Schein, Inc. $HSIC

Amundi increased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 93.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 188,314 shares of the company’s stock after purchasing an additional 91,082 shares during the period. Amundi owned approximately 0.16% of Henry Schein worth $14,026,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd bought a new position in Henry Schein during the second quarter worth $43,000. Steph & Co. acquired a new position in shares of Henry Schein during the second quarter valued at about $44,000. CX Institutional boosted its position in shares of Henry Schein by 107.3% during the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after purchasing an additional 337 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of Henry Schein by 103.0% in the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock valued at $49,000 after buying an additional 339 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd bought a new stake in Henry Schein in the 2nd quarter valued at about $62,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on HSIC. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Thursday, December 4th. Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Morgan Stanley lifted their price target on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Evercore ISI raised their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Finally, Wells Fargo & Company lifted their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $76.92.

Henry Schein Stock Up 1.9%

HSIC opened at $75.88 on Thursday. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The firm has a market capitalization of $8.93 billion, a P/E ratio of 24.01, a PEG ratio of 2.28 and a beta of 0.89. The company’s 50-day moving average is $68.80 and its 200 day moving average is $69.50. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The firm had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.